These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 31744222)
1. Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and Jeong HC; Bae SH; Bae JW; Lee S; Kim A; Jang Y; Shin KH Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31744222 [TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis of tramadol and Lee J; Yoo HD; Bae JW; Lee S; Shin KH Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765 [No Abstract] [Full Text] [Related]
3. Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes. Xu M; Zheng L; Zeng J; Xu W; Jiang X; Wang L Pharmacotherapy; 2021 Mar; 41(3):277-290. PubMed ID: 33316842 [TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition. Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318 [TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation. T'jollyn H; Snoeys J; Vermeulen A; Michelet R; Cuyckens F; Mannens G; Van Peer A; Annaert P; Allegaert K; Van Bocxlaer J; Boussery K AAPS J; 2015 Nov; 17(6):1376-87. PubMed ID: 26209290 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164 [TBL] [Abstract][Full Text] [Related]
7. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051 [TBL] [Abstract][Full Text] [Related]
8. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124 [TBL] [Abstract][Full Text] [Related]
9. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346 [TBL] [Abstract][Full Text] [Related]
10. Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats. Garrido MJ; Valle M; Campanero MA; Calvo R; Trocóniz IF J Pharmacol Exp Ther; 2000 Oct; 295(1):352-9. PubMed ID: 10992001 [TBL] [Abstract][Full Text] [Related]
11. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Fliegert F; Kurth B; Göhler K Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019 [TBL] [Abstract][Full Text] [Related]
12. Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration. Porażka J; Szałek E; Połom W; Czajkowski M; Grabowski T; Matuszewski M; Grześkowiak E Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):579-584. PubMed ID: 30778911 [TBL] [Abstract][Full Text] [Related]
13. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients. Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604 [TBL] [Abstract][Full Text] [Related]
14. Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms. Ahmadimanesh M; Naeini MB; Rouini MR; Shadnia S; Ghazi-Khansari M Drug Metab Pers Ther; 2020 Jun; ():. PubMed ID: 32598307 [TBL] [Abstract][Full Text] [Related]
15. PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN GIANT TORTOISES ( Yuschenkoff D; Cole GA; D'Agostino J; Lock B; Cox S; Sladky KK J Zoo Wildl Med; 2024 Mar; 55(1):86-91. PubMed ID: 38453491 [TBL] [Abstract][Full Text] [Related]
16. Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling. Jeong HC; Chae YJ; Lee S; Kang W; Yun HY; Shin KH J Clin Pharmacol; 2021 Nov; 61(11):1505-1513. PubMed ID: 34118174 [TBL] [Abstract][Full Text] [Related]
17. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients. Halling J; Weihe P; Brosen K Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. KuKanich B; Papich MG J Vet Pharmacol Ther; 2004 Aug; 27(4):239-46. PubMed ID: 15305853 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and antinociceptive effects of tramadol and its metabolite O-desmethyltramadol following intravenous administration in sheep. Bortolami E; Della Rocca G; Di Salvo A; Giorgi M; Kim TW; Isola M; De Benedictis GM Vet J; 2015 Sep; 205(3):404-9. PubMed ID: 26166406 [TBL] [Abstract][Full Text] [Related]
20. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Tzvetkov MV; Saadatmand AR; Lötsch J; Tegeder I; Stingl JC; Brockmöller J Clin Pharmacol Ther; 2011 Jul; 90(1):143-50. PubMed ID: 21562485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]